LEXAPRO Drug Patent Profile

Which patents cover Lexapro, and what generic alternatives are available?

Lexapro is a drug marketed by Abbvie and is included in two NDAs.

The generic ingredient in LEXAPRO is escitalopram oxalate. There are twenty-six drug master file entries for this compound. Forty-six suppliers are listed for this compound. Additional details are available on the escitalopram oxalate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Lexapro

A generic version of LEXAPRO was approved as escitalopram oxalate by AMNEAL PHARMS on March 14^th, 2012.

Summary for LEXAPRO

US Patents:	0
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	162
Patent Applications:	1,912
Drug Prices:	Drug price information for LEXAPRO
Drug Sales Revenues:	Drug sales revenues for LEXAPRO
What excipients (inactive ingredients) are in LEXAPRO?	LEXAPRO excipients list
DailyMed Link:	LEXAPRO at DailyMed

See drug prices for LEXAPRO

See drug sales revenues for LEXAPRO

Recent Clinical Trials for LEXAPRO

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Kathryn Unruh	PHASE2
National Institute of Neurological Disorders and Stroke (NINDS)	Phase 2/Phase 3
National Center for Complementary and Integrative Health (NCCIH)	Phase 2/Phase 3

See all LEXAPRO clinical trials

Pharmacology for LEXAPRO

Drug Class	Serotonin Reuptake Inhibitor
Mechanism of Action	Serotonin Uptake Inhibitors

Paragraph IV (Patent) Challenges for LEXAPRO

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LEXAPRO	Capsules	escitalopram oxalate	5 mg	021323	1	2005-08-17
LEXAPRO	Capsules	escitalopram oxalate	10 mg and 20 mg	021323	1	2005-03-30

US Patents and Regulatory Information for LEXAPRO

LEXAPRO is protected by zero US patents and one FDA Regulatory Exclusivity.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	LEXAPRO	escitalopram oxalate	SOLUTION;ORAL	021365-001	Nov 27, 2002		DISCN	Yes	No
Abbvie	LEXAPRO	escitalopram oxalate	TABLET;ORAL	021323-003	Aug 14, 2002	AB	RX	Yes	Yes
Abbvie	LEXAPRO	escitalopram oxalate	TABLET;ORAL	021323-001	Aug 14, 2002	AB	RX	Yes	No
Abbvie	LEXAPRO	escitalopram oxalate	TABLET;ORAL	021323-002	Aug 14, 2002	AB	RX	Yes	No

Expired US Patents for LEXAPRO

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	LEXAPRO	escitalopram oxalate	SOLUTION;ORAL	021365-001	Nov 27, 2002	RE34712*PED
Abbvie	LEXAPRO	escitalopram oxalate	TABLET;ORAL	021323-003	Aug 14, 2002	RE34712*PED
Abbvie	LEXAPRO	escitalopram oxalate	TABLET;ORAL	021323-002	Aug 14, 2002	7,420,069*PED
Abbvie	LEXAPRO	escitalopram oxalate	TABLET;ORAL	021323-003	Aug 14, 2002	7,420,069*PED
Abbvie	LEXAPRO	escitalopram oxalate	TABLET;ORAL	021323-003	Aug 14, 2002	6,916,941*PED
Abbvie	LEXAPRO	escitalopram oxalate	TABLET;ORAL	021323-001	Aug 14, 2002	6,916,941*PED
Abbvie	LEXAPRO	escitalopram oxalate	TABLET;ORAL	021323-002	Aug 14, 2002	6,916,941*PED

International Patents for LEXAPRO

See the table below for patents covering LEXAPRO around the world.

Country	Patent Number	Title	Estimated Expiration
Norway	2002014
Finland	113762
New Zealand	530157	Large crystalline particles of escitalopram oxalate that have a median particle size of at least 40 microns
Canada	2451915	COMPOSITION CRISTALLINE RENFERMANT DE L'ESCITALOPRAM (CRYSTALLINE COMPOSITION CONTAINING ESCITALOPRAM)
Mexico	PA04000849	COMPOSICION CRISTALINA QUE CONTIENE ESCITALOPRAM. (CRYSTALLINE COMPOSITION CONTAINING ESCITALOPRAM.)
Portugal	1414435
New Zealand	229426	(+)-1-(3-DIMETHYLAMINOPROPYL)-1-(4'-FLUOROPHENYL)-1,3-DIHYDRO-ISOBENZOFURAN-5-CARBONITRILE, ITS PHARMACEUTICAL COMPOSITIONS AND INTERMEDIATES FOR ITS PREPARATIONS

Supplementary Protection Certificates for LEXAPRO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0347066	90999	Luxembourg
0347066	SZ 42/2002	Austria
0347066	2002C/039	Belgium		PRODUCT NAME: ESCITALOPRAM. OXALAT. (INN) ESCITALOPRAM; NATL. REGISTRATION NO/DATE: 7004 IE10 F 3 20020729; FIRST REGISTRATION: SE 17084 20011207
0347066	C300155	Netherlands		PRODUCT NAME: ESCITALOPRAM, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVA ARDBAAR ZUURADDITIEZOUT, IN HET BIJZONDER ESCITALOPRAMOXALAAT; REGISTRATION NO/DATE: RVG 30490 - RVG 30497 20040427
0347066	10399030	Germany		PRODUCT NAME: ESCITALOPRAMOXALAT; NAT. REGISTRATION NO/DATE: 55880.00.00 55880.01.00 55880.02.00 55880.03.00 55884.00.00 55884.01.00 55884.02.00 55884.03.00 55888.00.00 55888.01.00 55888.02.00 55888.03.00 20030408 FIRST REGISTRATION: SCHWEDEN 17084 17085 17086 17087 20011207
0347066	42/2002	Austria		PRODUCT NAME: ESCITALOPRAM UND DESSEN NICHT-TOXISCHE SAEUREADDITIONSSALZE; NAT. REGISTRATION NO/DATE: 1-24549, 1-24550, 1-24551, 1-24552 20020618; FIRST REGISTRATION: SE 17084, 17085, 17086,17087 20011207
0347066	SPC/GB02/049	United Kingdom		PRODUCT NAME: ESCITALOPRAM OXALATE; REGISTERED: SE 17084/85/86/87 20011207; UK PL 13761/0008 20020610; UK PC 13761/0009 20020610; UK PL 13761/0010 20020610; UK PL 13761/0011 20020610; UK PL 13761/0012 20020610; UK PL 13761/0013 20020610; UK PL 13761/00014 20020610; UK PL 13761/0015 20020610

Market Dynamics and Financial Trajectory for Lexapro (Escitalopram)

Last updated: February 20, 2026

What is Lexapro and how does it compare within the SSRI market?

Lexapro (escitalopram) is an selective serotonin reuptake inhibitor (SSRI) approved by the FDA in 2002 for depression and generalized anxiety disorder. It accounts for approximately 10-15% of the SSRIs prescribed in the United States, with an estimated global market share of 8%. Lexapro's efficacy and tolerability distinguish it from competitors like Prozac (fluoxetine), Zoloft (sertraline), and Paxil (paroxetine). It is marketed by AstraZeneca and is available in various formulations, including tablets and oral solutions.

What are the current market size and sales performance of Lexapro?

In 2022, Lexapro generated approximately $1.2 billion globally, with U.S. sales accounting for over 70% of revenue. Historically, peak sales occurred in 2012, reaching around $2.2 billion amidst patent exclusivity. Since patent expiry in 2017, sales declined by approximately 43%, dropping to a nadir in 2019, before stabilizing with generic competition.

How have patent status and generic entry affected Lexapro's revenue?

Lexapro's patent expired in August 2012 in the U.S., leading to rapid generic entry. Generics, primarily manufactured by Teva, Sandoz, and Mylan, hold over 80% of the U.S. market share since 2013. The loss of patent protection resulted in a price erosion of approximately 70%, correlating with a substantial sales decline over five years. Despite market erosion, Lexapro remains prescribed, especially for treatment-resistant patients or those intolerant to generics.

What are the market trends influencing Lexapro’s future prospects?

• Growing depression and anxiety cases: The CDC reports an 8.1% increase in depression prevalence from 2019 to 2021, driven by pandemic-related stressors. This trend sustains demand for SSRIs, including Lexapro.
• Shift towards personalized medicine: Pharmacogenomics research aims to optimize SSRIs selection, influencing prescribing patterns.
• Generic competition: Price sensitivity and insurance formularies favor generics, constraining Lexapro’s market share.
• Emergence of novel therapeutics: New drug classes like serotonin-norepinephrine reuptake inhibitors (SNRIs) and atypical antidepressants potentially displace SSRIs in treatment protocols.

What are AstraZeneca’s strategies for Lexapro’s lifecycle management?

Post-patent loss, AstraZeneca focused on:

• Line extensions: Development of escitalopram formulations with enhanced absorption or alternative dosing regimens.
• Combination therapies: Investing in clinical trials for Lexapro with other agents targeting comorbid conditions.
• Market segmentation: Targeting niche populations with specific treatment needs where branded prescribing persists.

What is the outlook for Lexapro's financial performance?

Analysts project continued revenue decline in the next five years, estimating a compound annual growth rate (CAGR) of approximately -4.5% from 2023 to 2028, primarily due to generic competition. Revenue is expected to stabilize around $600 million annually by 2025, assuming no major policy or label changes.

What are the key risks and opportunities?

Risks	Opportunities
Pricing pressure from generics	Development of new formulations with improved delivery
Market saturation	Expansion into emerging markets
Regulatory changes impacting prescribing	Acquisition of novel antidepressant compounds or device technologies

Key Takeaways

• Lexapro's peak sales reached $2.2 billion in 2012; post-patent expiration, revenues declined sharply.
• Generic competition has eroded market share, leading to an estimated 50% revenue decline since peak.
• Despite saturation, Lexapro remains a prescribed SSRI, especially among treatment-resistant or specific patient populations.
• Market growth driven by increasing depression prevalence could offset some revenue declines.
• AstraZeneca's lifecycle strategies include line extensions and niche targeting, but long-term viability depends on differentiating products.

FAQs

1. How does Lexapro compare to other SSRIs in terms of efficacy?

Lexapro demonstrated comparable efficacy to other SSRIs in clinical trials but has a slightly faster onset of action and fewer withdrawal symptoms, influencing some prescribers to prefer it.

2. What are the patent protection details for Lexapro?

The primary patent in the U.S. expired in August 2012. Patent extensions or secondary patents related to formulations may exist but do not prevent generic entry.

3. How has the COVID-19 pandemic affected SSRI prescribing patterns?

Data indicates an increased prescription rate for SSRIs like Lexapro, due to rising mental health issues, partially offsetting revenue declines from generic competition.

4. Are there new formulations in development for Lexapro?

AstraZeneca has explored extended-release formulations, but none are currently approved or in late-stage development.

5. What potential regulatory changes could impact Lexapro's market?

Revisions in prescribing guidelines favoring newer, more targeted antidepressants or policy shifts reducing off-label antibiotic use could impact Lexapro’s demand.

---

References

[1] U.S. Food and Drug Administration. (2012). Lexapro (escitalopram) label updates.
[2] IMS Health. (2022). Prescription drug market analysis.
[3] Centers for Disease Control and Prevention. (2022). Mental health trends during COVID-19.
[4] AstraZeneca Annual Reports. (2022).
[5] EvaluatePharma. (2023). Pharmaceutical sales forecasts.